Neurogene Inc.NGNEEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Neurogene Inc. is a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for patients with rare, genetically driven neurological disorders that have significant unmet medical needs, with its primary operating markets spanning North America and Europe.
Revenue
$0
Gross Profit
N/A
Operating Profit
$-26.1M
Net Profit
$-22.0M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-1.05
Neurogene Inc. Q2 FY2025 Financial Summary
Neurogene Inc. reported revenue of $0 for Q2 FY2025, with a net profit of $-22.0M (down 19.1% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-22.0M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q2 FY2025 |
Neurogene Inc. Quarterly Revenue & Net Profit History
Neurogene Inc. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $0 | — | $-21.0M | N/A |
| Q2 FY2025 | $0 | — | $-22.0M | N/A |
| Q3 FY2024 | $0 | — | $-20.2M | N/A |
| Q2 FY2024 | $925.0K | — | $-18.5M | -1999.1% |
Income Statement
| Q2 2024 | Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Revenue | $925000 | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A |
Balance Sheet
| Q2 2024 | Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Assets | $179.8M | $164.1M | $297.3M | $287.8M |
| Liabilities | $24.8M | $26.7M | $24.1M | $22.3M |
| Equity | $155.0M | $137.4M | $273.3M | $265.5M |
Cash Flow
| Q2 2024 | Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Operating CF | $-15.9M | $-15.6M | $-19.5M | $-19.5M |